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School of Veterinary Medicine and Biomedical Sciences University of Nebraska – Lincoln, Lincoln, NE, USA
ABSTRACT

ARTICLE HISTORY

Ivermectin is widely used in both animals and humans as an FDA-approved parasiticide.
Ivermectin has also been reported to have antiviral activity against several viruses including
coronaviruses. There are reports that indicate ivermectin may have some role in diminishing
the disease caused by SARS-CoV-2, but the evidence is inconclusive. The objective of this study
was to determine if ivermectin was efficacious in inhibiting avian infectious bronchitis virus
(IBV, a coronavirus) replication in chicken embryos. Briefly, our approach was to use the
Massachusetts vaccine strain of IBV in combination with various doses of ivermectin and
then inoculate these preparations into chicken embryos to determine if IBV replication was
inhibited. The embryos were examined for IBV lesions and samples of chorioallantoic fluid were
collected for IBV RT-PCR analysis. Several trials were performed, and the results of our study
indicate that ivermectin did not inhibit IBV replication in chicken embryos.
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1. Introduction
During the first quarter of 2020 the COVID-19 pan
demic was spreading across the United States at an
alarming rate with many afflicted people being hospi
talized. The medical community developed extreme
interest in searching for drugs to combat the disease.
Many drugs received consideration. Although these
drugs were FDA approved, they were approved for
disease conditions and indications other than
COVID-19. Some of these drugs received much atten
tion in the popular press and included antiviral, antiinflammatory and anti-parasitic drugs. Drugs that were
evaluated included remdesivir, baricitinib, choloro
quine/hydroxychloroquine, famotidine, ivermectin
and others [1]. Ivermectin, which is widely used in
the medical and veterinary professions as
a parasiticide, received much attention after
Dr. Pierre Kory testified at a U.S. Senate and
Homeland Security and Governmental Affairs
Committee on Capitol Hill, 8 December 2020, and
stated: “ . . . that ivermectin is effectively a ‘miracle
drug’ against COVID-19”. [2]. Subsequently, the
National Institutes of Health issued guidelines on treat
ing COVID-19 with ivermectin and stated: “There are
insufficient data for the COVID-19 Treatment
Guidelines Panel (the Panel) to recommend either for
or against the use of ivermectin for the treatment of
COVID-19. Results from adequately powered, welldesigned, and well-conducted clinical trials are needed
to provide more specific, evidence-based guidance on
the role of ivermectin in the treatment of COVID-19”.
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[3]. Heidary and Gharebaghi published a systematic
review that included the antiviral effects of ivermectin
on various viruses [4]. This review reported on iver
mectin antiviral effects conducted in in vitro models
and included two avian viruses – Newcastle disease
virus (NDV) and avian influenza virus. These reports
piqued our interest in determining the potential of
using ivermectin to combat coronaviral diseases of
poultry. Therefore, the objective of this study was to
determine if ivermectin had antiviral efficacy against
the poultry coronavirus, avian infectious bronchitis
virus, using a chicken embryo model.

2. Materials and methods
2.1. Ethical statement
This study was conducted at the University of
Nebraska – Lincoln. The protocols were approved by
the Institutional Animal Care and Use Committee
(Project ID 2114).
2.2. Virus
The Massachusetts type of avian infectious bronchitis
live vaccine virus (Merial, Inc., Athens, GA) was used.
The same lot of vaccine virus was used for all trials.
The lyophilized virus was supplied in vials containing
5,000 chick doses per vial. The lyophilized vaccine was
first reconstituted with 10 mls sterile phosphate buf
fered saline (PBS) and then further diluted in PBS to
a final dilution of 1:5000. The virus was then titrated
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in 10-day-old chicken embryos as follows (briefly): 10fold serial dilutions of the vaccine virus were prepared
using sterile PBS. Twelve chicken embryos per dilu
tion were inoculated with 0.1 ml of diluted virus per
embryo by the chorioallantoic (CA) route. Embryos
were candled after 24 hours, and any dead embryos
were removed. Following a 72-hour incubation period
post-inoculation, approximately 0.5 ml of CA fluid
was withdrawn from each egg and submitted for
reverse transcriptase – polymerase chain reaction ana
lysis (RT-PCR, see below) and the embryos were
removed from their shells and examined for lesions.
After determining which embryos were positive and
negative by observing embryo lesions consistent with
IBV infections and corroborating these results with
RT-PCR, a median egg infectious dose (EID50) was
determined by a previously published method [5]. The
1:5000 diluted vaccine was found to contain 80 EID50
per ml.

2.3. Eggs
Specific pathogen-free (SPF) eggs obtained from Valo
BioMedia (Adel, IA) were used throughout the study.
The fertile SPF eggs were delivered to our facility and
were incubated in our laboratory to obtain the 10-dayold chicken embryos used in this study.

were then injected into embryonated eggs at 0.1 ml per
egg by the CA route within 30 minutes following
preparation.

2.6. Experimental design, trial 1
Trial 1 contained eleven groups of chicken embryos that
were inoculated at 10 days of incubation. Each group
contained five chicken embryos except for group 11,
which contained six. Groups 1 and 2 received no iver
mectin and served as negative and positive virus controls,
respectively. Groups 3 through 10 received ivermectin at
various doses and were either inoculated with IBV and
ivermectin or PBS (i.e. no virus) and ivermectin. The
amount of ivermectin per chicken embryo for each
group was as follows: groups 3 and 4 received 100 uM
(87.5 ug/ml), groups 5 and 6 received 50 uM (43.75 ug/
ml), groups 7 and 8 received 25 uM (21.9 ug/ml) and
groups 9 and 10 received 12.5 uM (11 ug/ml). Group 11
served as an uninoculated control group. The IBV inocu
lum consisted of 80 EID50 per chicken embryo. At
72 hours post-inoculation embryos were removed from
their eggs and grossly examined for signs of virus infec
tivity and/or ivermectin toxicity. Chorioallantoic fluid
was also removed from each embryo and a pooled sam
ple for each group of eggs was submitted for virus deter
mination by RT-PCR analysis. The experimental design
is also displayed in Table 1.

2.4. Virus detection
IBV infection of the embryos was determined by remov
ing the embryos and observing characteristic IBV
embryo lesions including stunting, curling, clubbing of
the embryo down and urate deposits in the kidneys.
These results were corroborated by testing the CA fluid
by RT-PCR. RT-PCR BioChek (Scarborough, ME;
https://www.biochek.com/poultry-pcr/ibv-pcr-infec
tious-bronchitis-virus-rna-test-kit/) kits were used, and
the assays were performed in the Nebraska Veterinary
Diagnostic Center as per the manufacturer’s instructions.
A sample was considered positive with a cycle threshold
(Ct) of 39 or less as per the manufacturer’s
recommendation.

2.5. Ivermectin
Agri-mectin® Agri Laboratories, Ltd. (St. Joseph, MO)
a 1% sterile solution was used. The molecular weight of
ivermectin is 875 g/mol and was used for dose determi
nation. The concentrations of ivermectin used for all
trials were prepared in sterile PBS and are specified
both in micromoles (uM) and in micrograms/millilitre
(ug/ml). The ivermectin was combined with the IBV
inoculum in separate sterile tubes prior to egg embryo
inoculation at room temperature. These preparations

2.7. Experimental design, trials 2 and 3
Trials 2 and 3 were conducted as displayed in Table 2
using a virus inoculum of 80 EID50 per chicken
embryo. Groups 1 and 2 were negative and positive
virus control groups, respectively, and received no
ivermectin. Groups 3 through 5 received virus
inoculum that had been combined with various con
centrations of ivermectin prior to inoculation. The
dose of ivermectin for groups 3 through 5 were 50
uM (43.75 ug/ml), 25 uM (21.9 ug/ml) and 12.5 uM
(11 ug/ml) respectively. The number of chicken
embryos inoculated per group are displayed in
Table 2. As in trial 1 above, the 10-day-old chicken
embryos were harvested 72 hours post inoculation,
removed from their shells, and examined for viral
lesions. Chorioallantoic fluid was collected from
each embryo and submitted for RT-PCR analysis.

2.8. Experimental design, trials 4 and 5
Trials 4 and 5 were conducted in the exact same way as
trials 2 and 3 except the numbers of chicken embryos
inoculated per group differed (see Table 3) and the
virus inoculum was increased to 800 EID50 per egg
embryo.
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Table 1. Results of trial 1.
Group
1
2
3
4
5
6
7
8
9
10
11

Ivermectin Dose
uM
ug/ml
0 (PBS)
0 (PBS)
0 (PBS)
0 (PBS)
100uM
87.5ug/ml
100uM
87.5ug/ml
50uM
43.75ug/ml
50uM
43.75ug/ml
25uM
21.9ug/ml
25uM
21.9ug/ml
12.5uM
11ug/ml
12.5uM
11ug/ml
0
0

No. Embryos
5
5
5
5
5
5
5
5
5
5
6

Virus
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
0

RT-PCR (Ct)
+ (23.71)
+ (18.46)
+ (14.16)
+ (12.78)
+ (14.97)
ND

No. Embryos with Lesions
None
5/5
3/5*
5/5
None
5/5
None
5/5
No
5/5
None

ND = not done *lesions not consistent with IBV lesions

Table 2. Results of trials 2 and 3.
Ivermectin Dose
uM
ug/ml

Group
Trial 2
1
2
3
4
5

0 (PBS)
0 (PBS)
50uM
25uM
12.5uM

Trial 3
1
2
3
4
5

0 (PBS)
0 (PBS)
50uM
25uM
12.5uM

No. Embryos

Virus

Embryos Positive
by RT-PCR

No. Embryo
with Lesions

0 (PBS)
0 (PBS)
43.75ug/ml
21.9ug/ml
11ug/ml

8
12
12
12
12

No
Yes
Yes
Yes
Yes

0/8
7/12
10/12
12/12
12/12

None
7/12
10/12
12/12
12/12

0 (PBS)
0 (PBS)
43.75ug/ml
21.9ug/ml
11ug/ml

5
10
12
12
12

No
Yes
Yes
Yes
Yes

0/5
7/10
10/12
12/12
12/12

None
7/10
10/12
12/12
12/12

No. Embryos

Virus

Embryos Positive
by RT-PCR

No. Embryo
with Lesions

Table 3. Results of trials 4 and 5.
Ivermectin Dose
uM
ug/ml

Group
Trial 4
1
2
3
4
5

0 (PBS)
0 (PBS)
50uM
25uM
12.5uM

0 (PBS)
0 (PBS)
43.75ug/ml
21.9ug/ml
11ug/ml

8
12
12
12
12

No
Yes
Yes
Yes
Yes

0/8
12/12
12/12
12/12
12/12

None
12/12
12/12
12/12
12/12

Trial 5
1
2
3
4
5

0 (PBS)
0 (PBS)
50uM
25uM
12.5uM

0 (PBS)
0 (PBS)
43.75ug/ml
21.9ug/ml
11ug/ml

10
11
11
11
11

No
Yes
Yes
Yes
Yes

0/10
11/11
11/11
11/11
11/11

None
11/11
11/11
11/11
11/11

3. Results
The results of trial 1 are summarized in Table 1. No
embryo lesions were observed nor were any RT-PCR
results positive for any of the embryos that did not
receive virus except for group 3. In group 3 (those
embryos that received the highest dose of ivermectin
(100 uM/87.5ug/ml) and no virus inoculum), three of
five embryos displayed lesions but were not positive
for IBV by RT-PCR. The three embryos appeared
stunted and hyperaemic compared to controls (see
Figure 1). Displayed in Figure 1A is an uninoculated
control embryo at 13 days of embryonation. Figure 1B
is the corresponding 13-day-old embryo that was
inoculated with 100 uM of ivermectin (but no IBV)

at 10 days of embryonation. The embryos are some
what obscured by the presence of the CA membrane
containing CA fluid; however, it can be observed that
the embryo in 1B is stunted (i.e. smaller) compared to
the embryo in 1A. The lesions displayed by these three
embryos were not typical of lesions induced by IBV.
The samples collected for RT-PCR analysis were
pooled samples for each group and corroborated the
results of embryo lesions due to virus infectivity (i.e.
groups 2, 4, 6, 8 and 10). Results of trial 1 provided no
indication of viral inhibition at any ivermectin dose.
The results of trials 2 through 5 are displayed in
Tables 2 and 3. The embryo lesions observed in the
virus-inoculated groups were corroborated with RTPCR results. However, in groups 2 and 3, in trials 2
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Figure 1. Chicken embryos at thirteen days embryonation. A. Uninoculated control embryo. B. Embryo inoculated at 10 days
embryonation with 0.1 ml of 100 uM ivermectin.

and 3, some embryos did not display the lesions typi
cal of IBV infected embryos and the corresponding
CA fluid samples were negative by RT-PCR. In groups
4 and 5 of trials 2 and 3, all embryos displayed lesions
typical of IBV infection and all CA fluid samples were
positive by RT-PCR. All embryos inoculated with IBV
in trials 4 and 5 displayed typical IBV lesions and were
positive by RT-PCR.

4. Discussion
This study was conducted using chicken embryos.
Although some may consider this an in vitro study
and recognizing that a chicken embryo is not
a fully developed animal, we ascertain an embryo
is more complex and emulates an in vivo model
more so than in vitro models which employ cul
tured cells. Therefore, some may consider the
results of studies using chicken embryos more
relevant than in vitro results using cell culture.
Also note that the use of chicken embryos was
vetted by our institutional animal use and care
committee.
Trial 1 was designed as a preliminary trial to
determine the effect of the IB vaccine virus on 10day-old chicken embryos and to evaluate the
potential toxicity of ivermectin. That is, trial 1
was designed as a pilot trial to ensure our virus
inoculum was infective and to evaluate any toxic
effects that ivermectin may have had on chicken
embryos in order for us to establish an ivermectin
dose range and an infective IBV dose for the
inoculum. Therefore, the experimental design
included several groups with small numbers of
chicken embryos in order to conserve resources
and to minimize the use of chicken embryos
while allowing us to explore an adequate dose
range. We chose to use 80 EID 50 as our IBV
inoculum. This was based on the work of others
using NDV in chicken embryo models to evaluate
the antiviral effects of ivermectin and other sub
stances in which 100 EID 50 was used as the

inoculum [6,7]. We realize that although NDV
and IBV are both single-stranded RNA viruses,
there are important differences between the two
and an inoculum of 80 EID50 may not have been
the optimum inoculum for our IBV chicken
embryo model. Perhaps 80 EID50 was not suffi
cient to infect all embryos therefore, we increased
the inoculum to 800 EID50 (please see below). Our
initial dose range of ivermectin in trial 1 was
determined by a previous published report by
Azeem, et al. who reported cytotoxic effects of
ivermectin using a chick primary embryo fibro
blast cell line at concentrations greater than 50
ug/ml [6]. Based on our data from trial 1, and
the report by Azeem et al., we attributed the
lesions observed in the embryos from group 3
(ivermectin with no virus) to be toxic effects of
ivermectin and we elected to eliminate the high
dose (100 uM/87.5 ug/ml) from trials 2 through 5.
In trials 2 through 5 the numbers of chicken
embryos per group varied in each trial due to the
availability of chicken embryos at the time of the
trial. In groups 2 and 3 of trials 2 and 3, not all
virus inoculated chicken embryos displayed IBV
lesions nor were they RT-PCR positive. Chicken
embryos in group 2 of both trials 2 and 3 served
as our positive IBV control groups. We expected all
chicken embryos to be positive for IBV. However,
as can be observed in Table 2, some chicken
embryos were not infected by IBV as determined
by the absence of embryo lesions and negative RTPCR results. Additionally, some chicken embryos in
group 3 for both trials 2 and 3 were also negative
for IBV. If IBV negative chicken embryos had been
found only in the high-dose ivermectin groups
(group 3, trials 2 and 3), then we may have con
sidered a viral inhibitory effect. However, since
there were so few negative eggs in group 3 and
realizing we had more negative eggs in group 2
(our positive viral control groups in trial 2 and 3)
than group 3, we considered these results as experi
mental error. Such experimental error may have
occurred in the inoculation procedure especially

INTERNATIONAL JOURNAL OF VETERINARY SCIENCE AND MEDICINE

since we were using a relatively low dose of virus
inoculum and placement of the inoculum may have
varied due to the lack of technical experience on
our part. Therefore, because a low number of
chicken embryos were negative for IBV in groups
2 and 3, in trials 2 and 3, we repeated the trials
increasing the viral inoculum by 10-fold (i.e. 800
EID50) in trials 4 and 5. As can be seen in Table 3
all virus inoculated chicken embryos were 100%
positive for IBV as determined by embryo lesions
and corroborated with RT-PCR results. One might
argue that we merely “overloaded” the model by
using a higher virus inoculum in trials 4 and 5.
That is a valid argument and point well taken.
However, since we observed no viral inhibition at
the lower virus inoculum in trials 2 and 3, we are
confident in stating that in the chicken embryo
model we employed, ivermectin did not inhibit
viral replication. Azeem et al. reported antiviral
activity with ivermectin using a similar chicken
embryo model and NDV. However, the ivermectin
concentrations exhibiting antiviral activity were
also considered cytotoxic [6].
Although SARS-CoV-2 and IBV are both corona
viruses we recognize there are important differences
between the two. One report states that the genomes of
the two viruses have only 43% identity [8]. SARS-CoV
-2 is a betacoronavirus and utilizes the angiotensin
converting enzyme 2 (ACE2) as its host cell receptor.
In contrast, IBV is a gammacoronavirus and utilizes
the sialic acid receptor [9–11]. SARS-CoV-2 does not
infect chickens or chicken embryos [12,13] and IBV
does not infect humans and has no known public
health concerns [11]. Therefore, the use of IBV
chicken embryo infection as a SARS-CoV-2 model
system should be carefully evaluated. It has been
reported that ivermectin has antiviral activity against
SARS-CoV-2 in an in vitro cell culture system [14].
Antiviral activity of ivermectin has also been shown to
occur in an in vitro cell culture system with an avian
influenza virus [15]. There are other reports of anti
viral activity of ivermectin against both RNA and
DNA viruses [4]. The results of this trial do not sup
port antiviral activity of ivermectin. However, under
different experimental conditions and/or formula
tions, perhaps ivermectin could exert antiviral activity
[16]. Perhaps adult chickens (or other animals) may be
more tolerant to higher doses of ivermectin and allow
antiviral activity to occur. It is recognized that there
are various ways to design these types of trials. The
rationale that was used in this study for combining the
IBV and drug (i.e. ivermectin) and inoculating the
chicken embryos was to ensure that the virus com
bined with the drug (i.e. ivermectin) were both depos
ited in the chicken embryo at precisely the same
location and thus decreasing the risk of having the
virus in one location (within the embryo) and the
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drug in another. This approach is frequently used in
virus neutralization assays when testing antisera.
Additionally, the rationale for combining the drug
and virus inoculum and administering it to the
chicken embryos within 30 minutes was to evaluate
the inhibition of virus replication and not virus inac
tivation. Had we found indications of antiviral effects
in our embryo model we would pursue further studies
in an attempt to find applications for ivermectin to be
used as an intervention/treatment strategy for corona
virus infections in poultry and other domestic ani
mals. However, based on the results of this study we
are less enthusiastic about pursuing further studies.
Negative research results are often deemed not
worthy of reporting. However, because of the public
health concerns and information being distributed
about ivermectin, we believe the results of this study
are germane. Unfortunately, there have been those
that have consumed veterinary formulations of iver
mectin in an apparent attempt to prevent or treat
COVID-19 resulting in hospitalization [17].

Conclusion
Therefore, we are compelled to report that we have no
laboratory results that support antiviral activity of ivermec
tin against the Massachusetts vaccine strain of IBV that is
used to prevent avian infectious bronchitis.
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